Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel
Authors:ID Žist, Andrej (Author)
ID Amir, Eitan (Author)
ID Ocaña, Alberto (Author)
ID Šeruga, Boštjan (Author)
Files:.pdf PDF - Presentation file, download (428,78 KB)
MD5: A4CD9CF5F1E82432370504002EB35416
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Men with metastatic castrate-resistant prostate cancer (mCRPC) may not receive docetaxel in everyday clinical practice due to comorbidities. Here we explore the impact of comorbidity on outcome in men with mCRPC treated with docetaxel in a population-based outcome study. Methods. Men with mCRPC treated with docetaxel at the Institute of Oncology Ljubljana between 2005 and 2012 were eligible. Comorbidity was assessed by the age-adjusted Charlson comorbidity index (aa-CCI) and adult comorbidity evaluation (ACE-27) index. Hospital admissions due to the toxicity and deaths during treatment with docetaxel were used as a measure of tolerability. Association between comorbidity and overall survival (OS) was tested using the Cox proportional hazards analysis. Results. Two hundred and eight men were treated with docetaxel. No, mild, moderate and severe comorbidity was present in 2%, 32%, 53% and 13% using aa-CCI and in 27%, 35%, 29% and 8% when assessed by ACE-27. A substantial dose reduction of docetaxel occurred more often in men with moderate or severe comorbidity as compared to those with no or mild comorbidity. At all comorbidity levels about one-third of men required hospitalization or died during treatment with docetaxel. In univariate analysis a higher level of comorbidity was not associated with worse OS (aa-CCI HR 0.99; [95% CI 0.87%1.13], p = 0.93; ACE-27: HR 0.96; [95% CI 0.79%1.17], p = 0.69).
Keywords:metastatic castration-resistant prostate cancer, prostate cancer, comorbidity, chemotherapy
Publication status:Published
Publication version:Version of Record
Publication date:01.12.2015
Publisher:Association of Radiology and Oncology
Year of publishing:2015
Number of pages:str. 402-408, VII
Numbering:Vol. 49, no. 4
Source:Ljubljana
PID:20.500.12556/DiRROS-18792 New window
UDC:616.6-006-08
ISSN on article:1318-2099
DOI:10.1515/raon-2015-0038 New window
COBISS.SI-ID:2215291 New window
Copyright:by Authors
Publication date in DiRROS:22.04.2024
Views:51
Downloads:18
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Keywords:prostata, rak (medicina), kemoterapija, pridružene bolezni


Back